详文均见于”最近进展”（除非另有说明）; 同一文章可能见于本节内不同分类
Full articles can be found under “Recent Progress” unless specified; same reports may be classified under different categories in this section
乳腺癌 Breast cancer
12/20/25 T-DXd作为新辅助治疗方案用于HER2阳性早期乳腺癌 T-DXd used in neoadjuvant treatment for HER2-positive early-stage breast cancer: DESTINY-Breast11
12/6/25 Patritumab deruxtecan 治疗非小细胞肺癌/乳腺癌伴活动性脑转移患者 Patritumab deruxtecan in non-small-cell lung cancer/breast cancer patients with brain metastases: TUXEDO-3 trial
11/23/25 T-DXd用于接受新辅助治疗后有残留浸润性癌的HER2阳性早期乳腺癌 T-DXd for HER2-positive early breast cancer with residual invasive carcinoma after neoadjuvant therapy: DESTINY-Breast05 trial
9/21/2025 三种 CDK4/6 抑制剂一线治疗晚期雌激素受体 (HR) 阳性/HER2 阴性乳腺癌真实世界疗效比较 Real-world efficacy comparison of three CDK4/6 inhibitors as first-line therapy for advanced estrogen receptor-Positive/HER2-Negative Breast Cancer: PALMARES-2
7/27/2025 Patritumab deruxtecan 治疗实体瘤软脑膜转移 Patritumab deruxtecan in metastatic leptomeningeal disease: phase 2 TUXEDO-3 trial
7/19/2025 Aprepitant 在化疗期间的使用与早期乳腺癌生存期的相关性 Aprepitant use during chemotherapy and association with survival in early breast cancer
7/5/2025 曲妥珠单抗德鲁替康 + 帕妥珠单抗对比紫杉烷/曲妥珠单抗/帕妥珠单抗用于HER2+ 晚期乳腺癌一线治疗 Trastuzumab deruxtecan + pertuzumab vs taxane + trastuzumab + pertuzumab as first-line treatment for HER2+ advanced breast cancer: Interim results from DESTINY-Breast09
5/25/2025 乳腺癌患者的手术延迟与死亡风险因亚型而异 Delayed surgery and mortality risk vary by breast cancer subtype
4/26/2025 最新进展 Recent Progress–>奥拉帕尼用于BRCA1/BRCA2+且高危HER2阴性乳腺癌患者（新）辅助化疗后疗效的长期随访 Long-term follow-up of adjuvant olaparib after (neo)adjuvant chemotherapy in germline BRCA1/BRCA2+ & high risk HER2- breast cancer: OlympiA trial
1/18/2025: FDA 批准 datopotamab deruxtecan-dlnk 用于治疗不可切除或转移性, HR 阳性、HER2 阴性乳腺癌 FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
1/5/2025: 蒽环类药物对复发评分>31淋巴结阴性 HR+/HER2- 乳腺癌的影响 Impact of anthracyclines in RS >31 node-negative HR+/HER2- breast cancer
1/4/2025: 新一代雌激素受体降解剂Imlunestrant+/-阿贝西尼治疗晚期乳腺癌 Next-generation ER degrader with or without abemaciclib for advanced breast cancer
肺癌 Lung cancer
12/21/25 新辅助奥希替尼治疗可切除EGFR突变非小细胞肺癌 Neoadjuvant osimertinib for resectable EGFR-mutated NSCLC: NeoADAURA trial
12/6/25 Patritumab deruxtecan 治疗非小细胞肺癌/乳腺癌伴活动性脑转移患者 Patritumab deruxtecan in non-small-cell lung cancer/breast cancer patients with brain metastases: TUXEDO-3 trial
11/15/25 SARS-CoV-2 mRNA疫苗可增强肿瘤对免疫检查点阻断疗法的敏感性 SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade
10/25/2025 奥希替尼联合化疗延长EGFR突变晚期肺癌生存期 Osimertinib and chemotherapy prolongs overall survival in EGFR-mutated advanced NSCLC: FLAURA2 trial
10/5/2025 立体定向放射后加用肿瘤治疗场延长脑转移性非小细胞肺癌患者的颅内响应时间 TTFields following SRS prolongs intracranial response in brain metastatic NSCLC
10/4/2025 两年固定疗程与持续性免疫检查点抑制剂治疗晚期非小细胞肺癌的疗效和安全性 Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced NSCLC
9/28/2025 ASCO 对治疗无驱动基因改变的非小细胞肺癌指南更新，包括首次比较免疫疗法 Update to ASCO guideline for NSCLC without driver alterations includes first comparison of immunotherapy options
9/13/2025 Dato-DXd 对脑转移的非小细胞肺癌患者的颅内效果 Intracranial response of Dato-DXd in patients with non-small cell lung cancer with brain metastases: TROPION-Lung01 trial
9/6/2025 Tarlatamab 对比化疗作为小细胞肺癌二线治疗 Tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer: DeLLphi-304 trial
8/23/2025 新辅助化疗联合纳武利尤单抗治疗肺癌改善了总生存期 Overall survival improved with neoadjuvant nivolumab plus chemotherapy in lung cancer
8/3/2025 Savolitinib与奥希替尼对MET+ 的 EGFR 突变型非小细胞肺癌的增强作用 Additional effect of savolitinib and osimertinib in MET+ EGFR-mutant non-small cell lung cancer
7/27/2025 Patritumab deruxtecan 治疗实体瘤软脑膜转移 Patritumab deruxtecan in metastatic leptomeningeal disease: phase 2 TUXEDO-3 trial
7/6/2025 Lurbinectedin 联合 Atezolizumab 维持治疗广泛期小细胞肺癌 Lurbinectedin with atezolizumab maintenance therapy in extensive-stage small-cell lung cancer
6/21/2025 Amivantamab 联合 lazertinib 与 osimertinib 治疗 EGFR 突变非小细胞肺癌的疗效对比 Amivantamab plus lazertinib vs osimertinib in EGFR-mutated NSCLC: MARIPOSA trial
2/17/2025: Zenocutuzumab 对 NRG1 融合阳性肺癌和胰腺癌的疗效 Efficacy of Zenocutuzumab in NRG1 fusion-positive non-small cell lung cancer and pancreatic cancer
1/12/2025: Metformin (二甲双胍)对肥胖症和肺癌预后和免疫治疗效果的改善 Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin
结直肠癌 Colorectal cancer
12/28/25 循环肿瘤DNA在Celecoxib治疗的III期结肠癌患者中的预测作用 Predictive role of circulating tumor DNA in stage III colon cancer treated with celecoxib: CALGB (Alliance)/SWOG 80702 trial
11/8/25 循环肿瘤DNA指导的局部晚期结肠癌辅助治疗 Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: Phase II/III DYNAMIC-III trial
11/1/25 长期服用质子泵抑制剂与50岁以下人群的早发性结直肠癌风险增加相关 Long-term PPI use associated with higher risk for early-onset colorectal cancer before age 50
8/30/2025 单独化疗或联合阿特珠单抗术后治疗DNA错配修复缺陷 III期结肠癌: 一项III随机试验 Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for stage III deficient DNA mismatch repair (dMMR) colon cancer: ATOMIC trial
6/28/2025 非手术治疗错配修复缺陷型肿瘤 Nonoperative management of mismatch repair–deficient (dMMR) tumors
4/6/2025 转移性结直肠癌的新型耦合 CAR T 疗法 GCC19CART 的 1 期研究 A phase 1 study of CAR T cell therapy, GCC19CART, for metastatic colorectal cancer
3/25/2024 单周期新辅助帕博利珠单抗治疗 MMR 缺陷结肠癌患 Single-cycle neoadjuvant pembrolizumab in patients with stage MMR-deficient colon cancer
3/9/2025: Invikafusp Alfa 用于PD-(L)1进展的结直肠癌 Invikafusp Alfa in PD-(L)1 refractory colorectal cancer
1/11/2025: 年轻人与老年人的结肠直肠癌发病率趋势：癌症登记数据分析 Colorectal cancer incidence trends in younger versus older adults: population-based cancer registry data
胰腺癌 Pancreatic cancer
8/2/2025 肿瘤电场治疗联合吉西他滨/白蛋白结合型紫杉醇治疗局部晚期胰腺癌 Tumor treating fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: Phase III PANOVA-3 study
5/24/2025 Tocilizumab联合化疗作为晚期胰腺癌一线治疗: 生存期和恶病质 Tocilizumab as first-line treatment in advanced pancreatic cancer: survival and cachexia
4/12/2025 大剂量静脉注射维生素C可能增加胰腺癌患者生存期 High-dose intravenous vitamin C may increase pancreatic cancer survival
2/17/2025: Zenocutuzumab 对 NRG1 融合阳性肺癌和胰腺癌的疗效Efficacy of Zenocutuzumab in NRG1 fusion-positive non-small cell lung cancer and pancreatic cancer
胃癌/胃食管癌 gastric/gastroesophageal cancer
6/7/2025 Trastuzumab deruxtecan 对比ramucirumab + 紫杉醇在HER 2 阳性转移性胃癌/胃食管腺癌二线治疗的疗效 Trastuzumab deruxtecan vs ramucirumab + paclitaxel in second-line treatment of HER2-positive metastatic gastric cancer or GE junction adenocarcinoma: phase III DESTINY-Gastric04
5/17/2025 III 期临床试验TFOX 对比 FOLFOX 在晚期胃或胃食管交界处腺癌者的一线治疗 TFOX versus FOLFOX in first-line treatment in advanced gastric or GE junction adenocarcinoma, a phase III trial
3/16/2025: CD47 髓系检查点抑制剂 evorpacept 用于HER2 过度表达的胃癌/胃食管癌患者的的 II/III 期研究 A CD47 myeloid checkpoint inhibitor evorpacept used in patients with HER2-overexpressing gastric/gastroesophageal cancer
胆道癌 Biliary tract cancer
7/13/2025 最新进展 Recent Progress–>Durvalumab 联合化疗治疗晚期胆道癌：III 期 TOPAZ-1 3 年总生存期更新 Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from TOPAZ-1 study
肛门癌 Anal cancer
6/1/2025 FDA 批准 retifanlimab-dlwr 与卡铂和紫杉醇联合治疗肛管鳞状细胞癌 FDA approves retifanlimab-dlwr in combination with carboplatin and paclitaxel for anal squamous cell carcinoma
3/2/2025: 肛门鳞状细胞癌的放射治疗：ASTRO 实践指南 Radiation therapy for anal squamous cell carcinoma: An ASTRO practice guideline
神经内分泌肿瘤 Neuroendocrine tumor
2/22/2025: 卡博替尼治疗晚期神经内分泌肿瘤的 III 期试验 Phase III trial of cabozantinib in advanced neuroendocrine tumors
1/26/2025: 依维莫司联合lanreotide相比于依维莫司单药治疗不可切除或复发性胃肠胰神经内分泌肿瘤 Everolimus combined with lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor
前列腺癌 Prostate cancer
5/10/2025 靶向CD46的抗体-药物（FG-3246）首次用于人类转移性前列腺癌的 I 期试验 First human phase I trial of antibody-drugs conjugate targeting CD46 (FG-3246) used in metastatic prostate cancer
3/15/2025: Talazoparib + 恩杂鲁胺一线治疗转移性去势抵抗性前列腺癌改善生存率 Talazoparib + enzalutamide as first-line treatment in metastatic castration-resistant prostate cancer (mCRPC) improved survival : TALAPRO-2 trial
尿路上皮癌 Urothelial cell cancer
11/29/25 问题解答–>输尿管尿路上皮细胞癌, Urothelial cell cancer of the ureter, Q&A
4/20/2025 添加抗组胺药有利于转移性尿路上皮癌的免疫疗法 Adding antihistamines benefited immunotherapy for metastatic urothelial carcinoma: IMvigor210 and IMvigor211 trials
膀胱癌 Bladder cancer
11/30/25 FDA批准帕博利珠单抗联合恩福妥单抗治疗肌层浸润性膀胱癌 FDA approved pembrolizumab in combination with enfortumab for muscle-invasive bladder cancer: KEYNOTE-905/EV-303
8/16/2025 TAR-200 治疗对卡介苗治疗无响应的高危非肌层浸润性膀胱癌 TAR-200 for BCG–unresponsive high-risk non–muscle-invasive bladder cancer: SunRISe-1 trial
肾细胞癌 Renal cell carcinoma
12/14/25 Belzutifan 延长晚期肾细胞癌患者的质量调整生存 Belzutifan prolongs quality-adjusted survival in advanced renal cell carcinoma
10/12/2025 贝伐单抗联合厄洛替尼治疗遗传性和散发性乳头状肾细胞癌 Bevacizumab and erlotinib in hereditary and sporadic papillary kidney cancer
6/14/2025 CAR T治疗晚期透明细胞肾细胞癌 (ccRCC)：1 期 TRAVERSE 研究 ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Phase I TRAVERSE study
5/18/2025 Casdatifan 单药治疗既往接受过治疗的透明细胞肾细胞癌: I期试验 Casdatifan in previously treated clear cell renal cell carcinoma, a phase I study
子宫内膜癌 Endometrial cancer
2/1/2025: 帕博利珠单抗联合辅助化疗（联合或不联合放疗）治疗高风险错配修复缺陷型子宫内膜癌 Pembrolizumab plus adjuvant chemotherapy +/- Radiotherapy for high-risk endometrial cancer: results in dMMR Tumors
卵巢癌 Ovarian cancer
12/13/2025 帕博利珠单抗联合每周紫杉醇可改善铂耐药复发性卵巢癌患者的生存结局 Pembrolizumab plus weekly paclitaxel improves survival in platinum-resistant recurrent ovarian cancer: ENGOT-ov65/KEYNOTE-B96
6/15/2025 Relacorilant 联合白蛋白结合型紫杉醇治疗铂耐药性卵巢癌患者 Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer: ROSELLA trial
5/11/2025 FDA 批准avutometinib和defactinib联合治疗KRAS突变复发性低级别浆液性卵巢癌 FDA approved avutometinib plus defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer
4/13/2025 卵巢癌衍生的IL-4促进免疫治疗抵抗, 阻断 IL-4 可能改善免疫治疗反应 Ovarian cancer-derived IL-4 promotes immunotherapy resistance, blocking IL-4 may improve immunotherapy response
4/5/2025 帕博利珠单抗联合化疗加上奥拉帕尼维持一线治疗晚期 BRCA 非突变性卵巢癌 Pembrolizumab plus chemotherapy followed by olaparib maintenance therapy as first-line treatment for advanced BRCA-nonmutated ovarian cancer: ENGOT-OV43/GOG-3036/KEYLYNK-001
头颈癌 Head and Neck cancer
9/7/2025 III 期试验评估术后纳武单抗联合放化疗治疗高风险头颈部鳞状细胞癌 Adjuvant nivolumab plus radio-chemotherapy in resected, high-risk head and neck squamous cell carcinoma: A phase III NIVOPOSTOP trial
6/21/2025 FDA 批准帕博利珠单抗用于可切除局部晚期头颈癌的新辅助和辅助治疗 FDA approves neoadjuvant and adjuvant pembrolizumab for resectable, locally advanced head and neck cancer
宫颈癌 Cervical Cancer
7/12/2025 FDA 批准了Teal Wand™ 用于宫颈癌筛查的家用阴道样本自采设备 FDA approves Teal Wand™, an at-home vaginal sample collection device for cervical cancer screening
3/16/2025: 帕博利珠单抗联合放化疗，随后使用帕博利珠单抗一线治疗局部晚期宫颈癌 Pembrolizumab owith chemoradiotherapy followed by pembrolizumab for newly diagnosed locally advanced cervical cancer: KEYNOTE-A18
鼻咽癌 Nasopharyngeal cancer
2/9/2025: 帕博利珠单抗联合或不联合贝伐单抗治疗铂类耐药性鼻咽癌 Pembrolizumab with or without bevacizumab in platinum-resistant nasopharyngeal carcinoma (NPC)
胸腺癌 Thymic cancer
3/29/2025 阿替利珠单抗联合卡铂和紫杉醇治疗晚期胸腺癌 Atezolizumab plus carboplatin and paclitaxel in advanced thymic carcinoma: MARBLE trial
胸膜间皮瘤 Pleural mesothelioma
9/27/2025 纳武单抗或纳武单抗联合伊匹单抗治疗可切除弥漫性胸膜间皮瘤 Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase II trial
甲状腺癌 Thyroid cancer
5/4/2025 ICAM-1 CAR-T 细胞 (AIC100) 治疗晚期甲状腺癌的 I 期研究 Phase I study of ICAM-1 CAR-T cells (AIC100) in advanced thyroid cancer
黑色素瘤 Melanoma
7/20/2025 RP1联合纳武单抗治疗抗PD-1治疗失败的晚期黑色素瘤 RP1 combined with nivolumab in advanced anti–PD-1–failed melanoma (IGNYTE)
5/31/2025 Niraparib 治疗伴同源重组途径基因突变的晚期黑色素瘤患者 Niraparib treating advanced melanoma with homologous recombination pathway gene mutations
3/8/2025: 纳武单抗+伊匹单抗用于抗 PD-1 治疗进展后的黑色素瘤脑转移 Intracranial outcome of ipilimumab and nivolumab for melanoma brain metastases following progression on anti–PD-1
3/1/2025: 伊匹单抗联合纳武单抗与单独使用纳武单抗治疗黑色素瘤脑转移患者：一项随机 II 期研究的 7 年随访 Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases: 7-year follow-up of a randomized, phase II study
淋巴瘤 Lymphoma
11/9/25 比较 Pola-R-CHP 和 R-CHOP 方案治疗弥漫性大 B 细胞淋巴瘤患者 Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma: POLARIX Study
9/20/2025 免疫疗法有效治疗表皮T细胞淋巴瘤 Durvalumab plus lenalidomide versus durvalumab in refractory/advanced cutaneous T cell lymphoma: a randomized phase II trial
8/24/2025 Glofitamab联合Pola-R-CHP或R-CHOP作为高危大B细胞淋巴瘤年轻患者的一线治疗 Glofitamab combined with Pola-R-CHP or R-CHOP as First Therapy in younger patients with high-risk large B-cell lymphoma: the COALITION Study
8/9/2025 Polatuzumab vedotin, 利妥昔单抗, 吉西他滨和奥沙利铂治疗复发/难治性弥漫大B细胞淋巴瘤 Pola-R-GemOx in patients with relapsed/refractory DLBCL : POLARGO trial
2/23/2025: 新型 CD19-1XX 嵌合抗原受体在大 B 细胞淋巴瘤中具有校准信号传导的首次人体 研究 First-in-human study of a novel CD19-1XX chimeric antigen receptor with calibrated signaling in large B-cell lymphoma
2/8/2025: BRUIN研究Pirtobrutinib治疗Richter转化的亚组分析 Subset analysis in BRUIN trial of Pirtobrutinib treating Richter transformation
多发性骨髓瘤 Multiple myeloma
12/7/25 Ciltacabtagene Autoleucel治疗的复发/难治性多发性骨髓瘤患者的长期缓解和生存情况 Long-term remission and survival in relapsed/refractory multiple myeloma following Ciltacabtagene Autoleucel: CARTITUDE-1 trial
10/18/2025 地塞米松减量方案治疗虚弱新诊断多发性骨髓瘤患者 Dexamethasone-sparing regimen in patients with frailty and newly diagnosed multiple myeloma: IFM2017-03 trial
肉瘤 Sarcoma
11/22/25 Nirogacestat 长期持续治疗硬纤维瘤的疗效和安全性 Efficacy and safety of long-term continuous Nirogacestat treatment in desmoid tumors: DeFi Trial
11/16/25 Mecbotamab vedotin在软组织肉瘤中有总生存期益处 Mecbotamab Vedotin shows positive overall survival benefit in soft tissue sarcoma
10/11/2025 ADCE-D01 用于治疗软组织肉瘤的临床试验: FDA 授予快速通道资格 Clinical trial using ADCE-D01 for soft tissue sarcoma: Granted fast track designation by FDA
1/25/2025: Siremadlin 和 ribociclib 用于晚期脂肪肉瘤 Siremadlin and ribociclib used in advanced liposarcoma
脑膜瘤/胶质母细胞瘤 Meningioma/glioblastoma
8/31/2025 加巴喷丁类药物可使胶质母细胞瘤患者有生存获益 Gabapentinoids confer survival benefit in human glioblastoma
1/19/2025: 177Lu-Dotatate 对手术和放射治疗无效的脑膜瘤患者的前瞻性 II 期研究 A prospective, phase II study of 177Lu-dotatate in Patients with surgery- and radiation-Refractory meningioma
肿瘤生物学和治疗/诊断新进展 Tumor biology & New treatment/diagnosis progress
11/15/25 SARS-CoV-2 mRNA疫苗可增强肿瘤对免疫检查点阻断疗法的敏感性 SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade
11/2/25 糖皮质激素治疗免疫检查点抑制剂引起的炎症性关节炎与癌症预后 Glucocorticoids for inflammatory arthritis due to ICI use and cancer outcomes
8/17/2025 拓扑异构酶I抑制剂的树枝状聚合物-纳米颗粒：在晚期实体瘤中的安全性及初步疗效 Dendrimer-nanoparticle delivery of topoisomerase I inhibitor, SN38: Safety and preliminary efficacy study in advanced solid tumors
7/27/2025 Patritumab deruxtecan 治疗实体瘤软脑膜转移 Patritumab deruxtecan in metastatic leptomeningeal disease: phase 2 TUXEDO-3 trial
7/26/2025 针对 TCR b 链靶向抗体 invikafusp alfa 用于治疗抗 PD(L)1 耐药的实体瘤 Invikafusp alfa, a TCR b-chain targeting antibody, treating anti-PD(L)1-resistant solid tumors
7/12/2025 FDA 批准了Teal Wand™ 用于宫颈癌筛查的家用阴道样本自采设备 FDA approves Teal Wand™, an at-home vaginal sample collection device for cervical cancer screening
6/28/2025 非手术治疗错配修复缺陷型肿瘤 Nonoperative management of mismatch repair–deficient (dMMR) tumors
6/8/2025 树脂毒素治疗顽固性癌痛 Treatment of intractable cancer pain with resiniferatoxin
5/3/2025 Zoldonrasib 用于 KRAS G12D 突变型 非小细胞肺癌 Zoldonrasib in patients with KRAS G12D–mutated NSCLC
4/20/2025 最新进展 添加抗组胺药有利于转移性尿路上皮癌的免疫疗法 Adding antihistamines benefited immunotherapy for metastatic urothelial carcinoma: IMvigor210 and IMvigor211 trial
4/13/2025 卵巢癌衍生的IL-4促进免疫治疗抵抗, 阻断 IL-4 可能改善免疫治疗反应 Ovarian cancer-derived IL-4 promotes immunotherapy resistance, blocking IL-4 may improve immunotherapy response
4/6/2025 转移性结直肠癌的新型耦合 CAR T 疗法 GCC19CART 的 1 期研究 A phase 1 study of CAR T cell therapy, GCC19CART, for metastatic colorectal cancer
3/9/2025: Invikafusp Alfa 用于PD-(L)1进展的结直肠癌 Invikafusp Alfa in PD-(L)1 refractory colorectal cancer
2/23/2025: 新型 CD19-1XX 嵌合抗原受体在大 B 细胞淋巴瘤中具有校准信号传导的首次人体 研究 First-in-human study of a novel CD19-1XX chimeric antigen receptor with calibrated signaling in large B-cell lymphoma
2/17/2025: Zenocutuzumab 对 NRG1 融合阳性肺癌和胰腺癌的疗效 Efficacy of Zenocutuzumab in NRG1 fusion-positive non-small cell lung cancer and pancreatic cancer
流行病学 Epidemiology
12/27/25 GLP-1受体激动剂对肥胖相关癌症风险可能影响甚微 GLP-1 RAs may have little effect on the risk of obesity-related cancers: Meta-analysis
11/1/25 长期服用质子泵抑制剂与50岁以下人群的早发性结直肠癌风险增加相关 Long-term PPI use associated with higher risk for early-onset colorectal cancer before age 50
9/14/2025 GLP-1受体激动剂与肥胖成人癌症风险 GLP-1 receptor agonists and cancer risk in adults with obesity
8/10/2025 个人护理产品中的甲醛和释放甲醛的防腐剂 Formaldehyde and formaldehyde releasing preservatives in personal care products
6/29/2025 最新进展 Recent Progress–>2010-2019年美国早发癌症发病率增加趋势 Trends in early-onset cancer incidence in the United States, 2010–2019
4/27/2025 人工智能触发的临床试验通知 Clinical trial notifications triggered by artificial intelligence-detected cancer progression
4/19/2025 美国胰腺癌和结直肠腺癌的发病率 Incidence of pancreas and colorectal adenocarcinoma in the US
3/30/2025 低水平砷暴露与肾癌风险之间的关系 Low-level arsenic exposure in drinking water and kidney cancer risk
2/2/2025: 多民族队列研究细颗粒物 (PM2.5)和乳腺癌发病率 PM2.5 and Breast Cancer Incidence in the Multiethnic Cohort Study